We aim to create a lasting and meaningful impact on patients suffering from cardiac conditions.
Cardiovascular diseases are a major burden and the first cause of death globally.
18+
Millions deaths/year
85%
caused by myocardial infarction & stroke
300
millions Disability-adjusted life years (DALY)
We unlock the potential of immunotherapies to reshape the future of Cardiovascular care. The momentum around emerging Cardio-immunology field has never been stronger.
We design monoclonal antibodies that specifically target the immune system's inflammatory pathways to prevent occurence and worsening of cardiovascular diseases.
Polygon is built on the high-impact academic work of Prof. Ait-Oufella, published in top-tier journals and primed for clinical translation. Led by skilled team with complementary expertise and backed by a scientific advisory board at the forefront of cardiology and inflammation, we are committed to turning breakthrough science into treatments that reach patients